Dr. Reddy's Laboratories Ltd.
DRREDDY · ISIN: INE089A01031
Dr. Reddy's Laboratories Ltd. is a mid cap company in the Pharmaceuticals & Biotechnology sector, listed on the NSE under ISIN INE089A01031.
Price and day-range figures above come from the latest NSE/BSE close, not a delayed quote. Where shown, RSI (14-day), SMA50/SMA200, and ADX measure momentum and trend from real daily closing prices - an RSI above 70 or below 30 typically signals overbought or oversold conditions, and a price above its SMA200 is a common long-term uptrend marker. ADTV (20-day average daily traded value) reflects real liquidity, not a projection. Fundamentals, when available, come from the company's own filed financials rather than a third-party estimate.
Constituent of NIFTY 100 TRI (0.58%), NIFTY 50 (0.72%), NIFTY 500 TRI (0.39%), NIFTY LMC 250 TRI (0.29%)
CHART
Dr. Reddy's Laboratories Ltd. - growth of ₹100
Growth of ₹100 invested on 2021-11-26, not raw price - the standard way to compare performance regardless of price level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.
1M
+9.08%
3M
+17.15%
6M
+1.67%
1Y
+4.78%
3Y CAGR
-37.66%
5Y CAGR
-
Earnings (TTM)
LEARN: Revenue and PAT · EPS · P/E
CHART
Dr. Reddy's Laboratories Ltd. - revenue & profit (TTM)
Trailing-twelve-month figures by reported quarter, in ₹ Cr. Latest quarter: 2026-09-30.
Technicals
As of 2026-10-29.
Shareholding Pattern
CHART
Shareholding by category
As of 2026-09-30.
F&O Sentiment
Nearest expiry: 2026-11-23 · As of 2026-10-28.
Corporate Actions
| Ex-Date | Type | Ratio | Details |
|---|---|---|---|
| 2024-10-28 | SPLIT | 0.200000 | FACE VALUE SPLIT (SUB-DIVISION) - FROM RS 5/- PER SHARE TO RE 1/- PER SHARE |
Recent Deals
| Date | Type | Quantity |
|---|---|---|
| 2026-10-28 | SHORT_SELL | 6,845 |
| 2026-10-27 | SHORT_SELL | 21,875 |
| 2026-10-22 | SHORT_SELL | 10 |
| 2026-10-21 | SHORT_SELL | 10 |
| 2026-10-13 | SHORT_SELL | 2,400 |
| 2026-10-12 | SHORT_SELL | 2 |
| 2026-10-08 | SHORT_SELL | 5 |
| 2026-10-07 | SHORT_SELL | 19,242 |
| 2026-09-29 | SHORT_SELL | 3,810 |
| 2026-09-28 | SHORT_SELL | 50 |
| 2026-09-22 | SHORT_SELL | 40,000 |
| 2026-09-21 | SHORT_SELL | 21,381 |
| 2026-09-17 | SHORT_SELL | 21,240 |
| 2026-09-15 | SHORT_SELL | 27,950 |
| 2026-09-10 | SHORT_SELL | 12,935 |
| 2026-09-03 | SHORT_SELL | 20 |
| 2026-08-18 | SHORT_SELL | 34,375 |
| 2026-08-17 | SHORT_SELL | 21,457 |
| 2026-08-14 | SHORT_SELL | 37,935 |
| 2026-08-13 | SHORT_SELL | 8,750 |
Frequently asked questions
What is Dr. Reddy's Laboratories Ltd.'s 1-year and 3-year return?
Dr. Reddy's Laboratories Ltd.'s 1-year price return is +4.78%. Its 3-year CAGR (annualized return) is -37.66%. Both are price-only returns (no dividends added back), computed from the nearest available trading day to each anniversary - not a forecast of future performance.
What is Dr. Reddy's Laboratories Ltd.'s latest financial performance?
Dr. Reddy's Laboratories Ltd.'s trailing-twelve-month (TTM) revenue as of 2026-09-30 is ₹33,097 Cr, with a TTM profit after tax of ₹2,760 Cr and an EBITDA margin of 7.9%. TTM figures sum the most recent four reported quarters rather than a single quarter, which smooths out seasonal swings in a business's revenue and profit. EPS (earnings per share) over this TTM window is ₹33.61, with a 5-year EPS growth rate of 8.38% - a rough proxy for how consistently the company has grown per-share earnings over a full market cycle.
What is Dr. Reddy's Laboratories Ltd.'s quality score?
Dr. Reddy's Laboratories Ltd. has a Punji quality score of 63.6 out of 100 as of 2026-09-30. This composite score is computed from the company's reported fundamentals (profitability, balance-sheet strength, and consistency of earnings, among other factors) and is designed to be comparable across companies in different sectors. A higher score indicates a fundamentally stronger business by these measures, though it isn't a price target or a buy/sell signal - a high-quality company can still be expensively priced, and a lower-scoring one can still be a reasonable investment at the right valuation.
What do Dr. Reddy's Laboratories Ltd.'s technical indicators show?
As of 2026-10-29, Dr. Reddy's Laboratories Ltd.'s RSI (14-day) is 74.5 - readings above 70 typically signal an overbought stock, below 30 an oversold one, so this reading sits in overbought territory. Its 50-day moving average is currently below its 200-day moving average, a "golden cross" setup when the shorter average is above (often read as a bullish medium-term signal) or a "death cross" when below (often read as bearish). These are backward-looking statistical measures, not predictions of future price movement.
Who are the major shareholders of Dr. Reddy's Laboratories Ltd.?
As of 2026-09-30, Dr. Reddy's Laboratories Ltd.'s shareholding is split across Promoter (26.63%), Public (73.17%), NonPromoterNonPublic (null%). Promoter holding of 26.63% indicates the founders/controlling group's own stake in the company - a higher promoter holding is often read as a sign of management's confidence in the business, though it should be considered alongside pledge status and recent buying/selling activity, which this figure alone doesn't capture.
Is Dr. Reddy's Laboratories Ltd. part of any major market index?
Yes - Dr. Reddy's Laboratories Ltd. is a constituent of NIFTY 100 TRI (0.58% weight) and NIFTY 50 (0.72% weight) and NIFTY 500 TRI (0.39% weight) and NIFTY LMC 250 TRI (0.29% weight). Index membership means the stock is automatically bought by every index fund and ETF tracking that benchmark, in proportion to its weight, which brings a baseline level of passive-fund demand independent of active investor sentiment. A stock's weight in an index is typically determined by its free-float market capitalization relative to the index's other constituents, and is periodically rebalanced as relative market caps shift.
What does the F&O market show for Dr. Reddy's Laboratories Ltd.?
As of 2026-10-28 (nearest expiry 2026-11-23), Dr. Reddy's Laboratories Ltd.'s put-call ratio by open interest is 1.0851 - above 1, typically read as bearish positioning (more open interest on puts than calls). The max pain strike is ₹1300, the price at which option writers as a group would owe the least to option buyers at expiry - a reference level some traders watch, not a price target. F&O positioning reflects derivatives-market sentiment over a specific expiry window, not a fundamental view on the company.
Has Dr. Reddy's Laboratories Ltd. seen any recent bulk or block deals?
Yes, as of 2026-10-28 - the most recent recorded deal was a SHORT_SELL on 2026-10-28 for 6,845 shares. Bulk and block deals are large trades (above exchange-defined thresholds) that must be publicly disclosed, and are often watched as a signal of institutional or high-net-worth investor conviction - though a single deal doesn't establish a trend, and the counterparty's reasons for buying or selling aren't disclosed alongside the trade itself.
What corporate actions has Dr. Reddy's Laboratories Ltd. announced recently?
The most recent corporate action for Dr. Reddy's Laboratories Ltd. is a SPLIT (0.200000) with an ex-date of 2024-10-28, for: FACE VALUE SPLIT (SUB-DIVISION) - FROM RS 5/- PER SHARE TO RE 1/- PER SHARE. The ex-date is the cutoff - only shareholders who held the stock before this date qualify for the action (dividend, split, bonus, or rights issue, depending on type). Corporate actions typically adjust the stock's price and/or share count mechanically on the ex-date, which is why historical price charts are usually shown adjusted for these events.
Stock data · Not financial advice · Past performance does not indicate future returns